Viatris Inc.

Company Snapshot

Founded: 2020
Entity Type: Public
Employees: 30,000
Region: North America and Europe
Revenue: $14,250.4 Millions
Revenue Year: 2025
Headquarter: Pennsylvania, U.S.
Key Geographics: North America, Europe, Asia-Pacific, Rest of the World
Corporate Address: 1000 Mylan Blvd., Canonsburg, PA 15317, U.S. Tel. +1-724-514-1800 www.viatris.com

Company Overview

Viatris Inc., a global pharmaceutical company, was formed in November 2020 by merging Mylan N.V. and Pfizer Inc.’s Upjohn division. It operates across numerous countries with a diverse portfolio of generic drugs and biosimilars. The company operates its business through three main segments: brands, generics and others.

Financial Highlights (FY 2025)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Viatris Inc. In Reports

Global Oncology Biosimilars Market

According to BCC Research detailed report on oncology biosimilars market analysis was for the base year 2024, with projections for 2025 to 2030.

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

BCC Research expert says the Therapies for Rheumatoid Arthritis market report analyzes the market trends of therapies for rheumatoid arthritis with data from 2024, estimates from 2025, projections of CAGR through 2030. ...

Global Markets for Allergy Diagnostics and Treatments

BCC Research Market Analyst says global market for allergy diagnostics and treatment is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030.

Company's Business Segments

  • Brands : Lipitor, Norvasc, Caduet, Inspra, Nitrostat, Revatio, Dilatin, Lyrica, Neurontin, Relpax
  • Generics : Wixela, Inhub, ADVAIR DISKUS, Glatiramer acetate injection, Copaxone

Applications/End User Industries

  • Governments
  • Healthcare Providers
  • Consumer
  • Pharmaceuticals
  • Technology Partners and Patients
AI Sentiment